Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.

[1]  Arl Medford,et al.  British Thoracic Society , 2004 .

[2]  P. Nikolaides,et al.  Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment , 2002, Antimicrobial Agents and Chemotherapy.

[3]  M. Leinonen,et al.  role of serum troponin levels combined with electrocardiographic findings Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines , 2001 .

[4]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.

[5]  A. Torres,et al.  Severity assessment in community-acquired pneumonia. , 2000, The European respiratory journal.

[6]  D. Sahm,et al.  Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States , 2000, Antimicrobial Agents and Chemotherapy.

[7]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M E Brier,et al.  Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. , 1999, Archives of internal medicine.

[9]  R. Pinner,et al.  Trends in infectious disease mortality in the United States during the 20th century. , 1999, JAMA.

[10]  M. Pfaller,et al.  Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  E. Haponik,et al.  Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. , 1998, Respiratory medicine.

[12]  M. Fine,et al.  Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. , 1998, JAMA.

[13]  M. Fine,et al.  Quality of care, process, and outcomes in elderly patients with pneumonia. , 1997, JAMA.

[14]  J. Kahn,et al.  Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. , 1997, Diagnostic microbiology and infectious disease.

[15]  T. File,et al.  A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia , 1997, Antimicrobial agents and chemotherapy.

[16]  J. Guest,et al.  Community-acquired pneumonia: the annual cost to the National Health Service in the UK. , 1997, The European respiratory journal.

[17]  G. Doern,et al.  In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis , 1997, Antimicrobial agents and chemotherapy.

[18]  G. Doern,et al.  Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study , 1997, Antimicrobial agents and chemotherapy.

[19]  D. Nicolau,et al.  Streamlining antimicrobial therapy for lower respiratory tract infections. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[21]  S M Teutsch,et al.  Trends in infectious diseases mortality in the United States. , 1996, JAMA.

[22]  M. Fine,et al.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. , 1996, JAMA.

[23]  J. Ramirez,et al.  Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. , 1995, Archives of internal medicine.

[24]  V L Yu,et al.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. , 1993 .

[25]  M. Fisch,et al.  Predicting death in patients hospitalized for community-acquired pneumonia. , 1991, Annals of internal medicine.